New cell therapy tested for Tough-to-Treat cancers
NCT ID NCT06562647
Summary
This early-stage study is testing a new cell-based therapy called SY001 in people with advanced ovarian or pancreatic cancer that has not responded to prior treatments. The main goals are to find a safe dose, see how the body handles the treatment, and check for any early signs that it might help control the cancer. It is a small, first-in-human trial designed to gather initial safety data before larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linyi Cancer Hospital
NOT_YET_RECRUITINGLinyi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.